Skip to main content
 

Investors & Media

Corporate Profile
At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi.
Recent News
June 8, 2017
ReadCoor and WAVE Life Sciences Initiate Research Collaboration
Collaboration aims to unlock next generation stereopure nucleic acid targets with novel FISSEQ technologies CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 8, 2017-- ReadCoor, Inc., a company reinventing omics and pathology with its panomic spatial sequencing platform, and WAVE Life Sciences Ltd. (NASDAQ:WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced the initia... 
June 6, 2017
WAVE Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will be participating at the following upcoming investor conferences: Jefferies 2017 Global Healthcare Conference – WAVE Company Presentation Wednesday, ... 
May 10, 2017
WAVE Life Sciences Reports First Quarter 2017 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 10, 2017-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced financial results for the first quarter ended March 31, 2017. “The beginning of 2017 was marked by continued advancement of our lead programs in HD and DMD and substantial progress in our collaboration with Pfizer. Our two HD pro... 

view all

Upcoming Events
There are currently no events scheduled.

view all